14 completed, 5 terminated, 3 withdrawn. 22 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 14, Terminated 5, Withdrawn 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Gastrinoma: new trials by email Literature Review of Gastrinoma trials Research Report on Gastrinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Terminated | Emory University | 2 | 2014-11-01 | 2017-02-03 |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery everolimus, placebo - Gastrinoma, Glucagonoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 2 | 2014-04-10 | 2023-06-29 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors temozolomide, capecitabine - Gastrinoma, Glucagonoma | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 144 | 2013-08-08 | 2026-09-29 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors capecitabine, cisplatin, streptozocin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 84 | 2005-08-01 | 2013-08-07 |
| Capecitabine and Temozolomide for Neuroendocrine Cancers Capecitabine, Temozolomide - Neuroendocrine Tumors | Phase 2 | Completed | Columbia University | 41 | 2005-08-01 | 2016-07-25 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors bevacizumab, 5-fluorouracil, leucovorin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 36 | 2005-06-08 | 2023-05-22 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors sorafenib tosylate - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2005-06-01 | 2014-11-17 |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery fluorouracil, irinotecan hydrochloride, leucovorin calcium - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 20 | 2004-05-01 | 2016-05-30 |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors romidepsin, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2004-03-01 | 2013-06-04 |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors gefitinib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 90 | 2003-12-01 | 2013-06-04 |
| Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors octreotide acetate, yttrium Y 90 resin microspheres - Head and Neck Cancer, Islet Cell Tumor | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 10 | 2003-12-01 | 2012-05-18 |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors EPO906 epothilone B - Carcinoid, Neuroendocrine Tumors | Phase 2 | Completed | Novartis Pharmaceuticals | 33 | 2002-07-01 | 2017-03-01 |
| PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors bortezomib - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 2001-04-01 | 2013-01-31 | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors thalidomide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-03-01 | 2013-06-18 | |
| The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Pantoprazole, Omeprazole - Gastrinoma, Zollinger Ellison Syndrome | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1983-02-03 | 2017-07-02 |
Showing 20 of 22. Sign in to see all of them.
Insulinoma (18) · Somatostatinoma (18) · Glucagonoma (17) · Carcinoma, Islet Cell (16) · Vipoma (11) · Adenoma, Islet Cell (9) · Neoplasms (6) · Neuroendocrine Tumors (6) · Carcinoid Tumor (3) · Neoplasm Metastasis (3) · Zollinger-Ellison Syndrome (3) · Carcinoma, Medullary (2) · Lung Neoplasms (2) · Pancreatic Neoplasms (2)
Adenocarcinoma (22) · Digestive System Diseases (22) · Digestive System Neoplasms (22) · Endocrine Gland Neoplasms (22) · Endocrine System Diseases (22) · Neoplasms by Histologic Type (22) · Neoplasms by Site (22) · Neoplasms, Glandular and Epithelial (22) · Pancreatic Diseases (22) · Carcinoma (21) · Carcinoma, Neuroendocrine (20) · Neoplasms, Germ Cell and Embryonal (20) · Neuroectodermal Tumors (20) · Pancreatic Neoplasms (20) · Adenoma (19)
Capecitabine (4) · Fluorouracil (3) · Octreotide (3) · Temozolomide (3) · Bevacizumab (2) · Everolimus (2) · Leucovorin (2) · Streptozocin (2) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Biological Therapy (1) · Bortezomib (1) · Cisplatin (1) · Doxorubicin (1) · Gefitinib (1)
National Cancer Institute (NCI) (3) · ECOG-ACRIN Cancer Research Group (2) · Eastern Cooperative Oncology Group (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Academic and Community Cancer Research United (1) · British Columbia Cancer Agency (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Columbia University (1) · Emory University (1) · Federation Francophone de Cancerologie Digestive (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · Ohio State University Comprehensive Cancer Center (1) · Shaheen Shagufta (1) · University of California, San Francisco (1)
United States (17) · Canada (1) · United Kingdom (1)
Mary Mulcahy, MD (2) · Timothy Hobday (2) · Emily Bergsland (1) · Emily K. Bergsland, MD (1) · Francois Benard, MD (1) · Guillaume Cadiot (1) · Kyle Holen, MD (1) · Leonard B. Saltz, MD (1) · Manisha H. Shah, MD (1) · Manisha Shah (1) · Pamela Kunz (1) · Paul E Oberstein, MD (1) · Pippa Corrie, PhD, FRCP (1) · R. Donald Harvey, PharmD (1)
PMID 21831734, PMID 29853660, PMID 36260828
N01CM62205 (2), U10CA021115 (2), P30CA014089 (1), U01CA076576 (1), U10CA023318 (1), U10CA180820 (1)